Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.82 and traded as high as $1.73. Cortexyme shares last traded at $1.70, with a volume of 522,822 shares.
Cortexyme Price Performance
The business’s 50 day simple moving average is $0.90 and its 200-day simple moving average is $0.82. The stock has a market capitalization of $51.26 million, a P/E ratio of -0.57 and a beta of 1.40.
Cortexyme Company Profile
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
See Also
- Five stocks we like better than Cortexyme
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- What Are Growth Stocks and Investing in Them
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
